Cerebrospinal fluid markers for DLB (review article)
The UK authors of this review article believe that a combination of cerebrospinal fluid measures may be able to differentiate DLB from Alzheimer's Disease and other dementias.
Remember that these authors are talking about DLB - Dementia with Lewy Bodies. They are *not* talking about PDD - Parkinson's Disease Dementia.
The full paper is available at no cost from the journal's website here:http://www.sage-hindawi.com/journals/ij ... 36538.html
(PDF and HTML versions are available)
Most of it is very dense.
I've copied the abstract below.
International Journal of Alzheimers Disease. 2010 Oct 17;2010:536538.
Cerebrospinal fluid biomarkers for dementia with lewy bodies.
Mukaetova-Ladinska EB, Monteith R, Perry EK.
Institute for Ageing and Health, Campus for Ageing and Vitality, Newcastle University, Newcastle upon Tyne, UK.
More than 750,000 of the UK population suffer from some form of cognitive impairment and dementia. Of these, 5-20% will have Dementia with Lewy Bodies (DLB).
Clinico-pathological studies have shown that it is the low frequency of DLB clinical core features that makes the DLB diagnosis hardly recognisable during life, and easily misdiagnosed for other forms of dementia. This has an impact on the treatment and long-term care of the affected subjects.
Having a biochemical test, based on quantification of a specific DLB biomarker within Cerebrospinal Fluid (CSF) could be an effective diagnostic method to improve the differential diagnosis.
Although some of the investigated DLB CSF biomarkers are well within the clinical criteria for sensitivity and specificity (>90%), they all seem to be confounded by the contradictory data for each of the major groups of biomarkers (a-synuclein, tau and amyloid proteins).
However, a combination of CSF measures appear to emerge, that may well be able to differentiate DLB from other dementias: alpha-synuclein reduction in early DLB, a correlation between CSF alpha-synuclein and AÃ42 measures (characteristic for DLB only), and t-tau and p-tau181 profile (differentiating AD from DLB).
PubMed ID#: 21048932